Galapagos (NL:GLPG)
:GLPG
Want to see NL:GLPG full AI Analyst Report?
Top Page
Galapagos
(GLPG)
Select Model
Select Model
Rating:71Outperform
Price Target:
€27.00
▲(9.31% Upside)
Action:UpgradedDate:02/25/26
The score is primarily supported by a very strong, low-leverage balance sheet and an improved 2025 income statement, tempered by the most significant risk: consistently negative operating and free cash flow. Technicals are modestly constructive (price above key moving averages) and valuation is favorable on a low P/E, though there is no dividend yield support.
Positive Factors
Balance sheet strength
Extremely low leverage and multi-billion euros of equity give durable financial flexibility. Over a 2-6 month horizon this supports continued R&D investment, ability to absorb cash burn, and negotiating leverage with partners without near-term refinancing pressure.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow, even after improvement, means the company remains reliant on cash reserves or future financing to fund ongoing operations and R&D. Over months this raises refinancing, dilution or program-scaling risk if cash generation does not reaccelerate.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Extremely low leverage and multi-billion euros of equity give durable financial flexibility. Over a 2-6 month horizon this supports continued R&D investment, ability to absorb cash burn, and negotiating leverage with partners without near-term refinancing pressure.
Read all positive factors
Galapagos (GLPG) vs. iShares MSCI Netherlands ETF (EWN)
Market Cap
€1.62B
Dividend YieldN/A
Average Volume (3M)132.01K
Price to Earnings (P/E)5.7
Beta (1Y)0.69
Revenue GrowthN/A
EPS GrowthN/A
CountryNL
Employees704
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)11.87
Shares Outstanding65,897,070
10 Day Avg. Volume76,560
30 Day Avg. Volume132,014
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€25.85Price Target Upside4.66% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering4
EPS Forecast (FY)-2.08
Revenue Forecast (FY)€81.19M
Galapagos Business Overview & Revenue Model
Company Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various pha...
How the Company Makes Money
Galapagos makes (or has made) money primarily through (1) collaboration and licensing arrangements with pharmaceutical partners—typically including upfront payments, research funding/reimbursements, development and regulatory milestone payments, s...
Galapagos Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
92
Very Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.11B | 275.65M | 239.72M | 505.28M | 484.85M |
| Gross Profit | 1.08B | 240.79M | 203.74M | 493.20M | 483.22M |
| EBITDA | 469.66M | 43.33M | 43.38M | -33.37M | -100.93M |
| Net Income | 320.88M | 74.08M | 211.70M | -217.99M | -125.42M |
Balance Sheet | |||||
| Total Assets | 3.41B | 4.14B | 4.36B | 4.73B | 5.19B |
| Cash, Cash Equivalents and Short-Term Investments | 3.00B | 3.12B | 3.68B | 4.09B | 4.70B |
| Total Debt | 12.10M | 11.72M | 9.60M | 21.90M | 26.86M |
| Total Liabilities | 170.65M | 1.24B | 1.56B | 2.21B | 2.55B |
| Stockholders Equity | 3.24B | 2.90B | 2.80B | 2.53B | 2.64B |
Cash Flow | |||||
| Free Cash Flow | -210.71M | -402.14M | -425.24M | -537.49M | -561.71M |
| Operating Cash Flow | -197.01M | -320.03M | -405.97M | -500.54M | -503.83M |
| Investing Cash Flow | 228.37M | 220.60M | 71.19M | -1.25B | 541.24M |
| Financing Cash Flow | -3.27M | -4.92M | -5.00M | -1.49M | -3.88M |
Galapagos Technical Analysis
Negative
24.70
Price Trends
27.31
Negative
27.58
Negative
27.66
Negative
Market Momentum
-0.90
Positive
37.03
Neutral
40.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:GLPG, the sentiment is Negative. The current price of 24.7 is below the 20-day moving average (MA) of 25.58, below the 50-day MA of 27.31, and below the 200-day MA of 27.66, indicating a bearish trend. The MACD of -0.90 indicates Positive momentum. The RSI at 37.03 is Neutral, neither overbought nor oversold. The STOCH value of 40.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NL:GLPG.
Galapagos Peers Comparison
UnderperformOutperform
Sector (55)
NL:GLPG
Galapagos
24.70
2.86
13.10%
NL:PHARM
Pharming Group
1.49
0.79
112.98%
NL:VVY
Vivoryon Therapeutics AG
1.35
-0.41
-23.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.